Macrogenics Inc

NASDAQ:MGNX  
19.74
-1.31 (-6.22%)
Products

MacroGenics Says Preliminary Clinical Results From Phase 1 Cohort Expansion Of The Ongoing Mgc018 Study Presented At ESMO 2021 Virtual Annual Congress

Published: 09/16/2021 06:56 GMT
Macrogenics Inc (MGNX) - Macrogenics - Preliminary Clinical Results From Phase 1 Cohort Expansion of the Ongoing Mgc018 Study Presented at Esmo 2021 Virtual Annual Congress.
Adverse Events for Dose Expansion Cohorts of 3 Mg/kg Were Generally Consistent With Those Previously Reported at Asco 2021.
Macrogenics -metastatic Castration-resistant Prostate Cancer (mcrpc): 21 of 39 Patients (54%) Achieved ≥ 50% Prostate-specific Antigen (psa) Reduction.